August 11, 2026

To, **BSE Limited**, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 **Ref:** Company Scrip Code: 532834	To, Listing Department, **National Stock Exchange of India Ltd.**, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 **Ref:** Symbol: CAMLINFINE || Series: EQ

Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

This is in continuation to our disclosure dated August 4, 2026 in relation to the conference call to discuss the Un-audited financial results of the Company for the quarter ended June 30, 2026, please find enclosed herewith the investor presentation made for the aforesaid call.

It is clarified that the presentation and the information contained therein does not constitute or form part of an invitation or solicitation to offer to purchase or subscribe to any securities of the Company in any jurisdiction. This presentation has been prepared for information purposes only. The information contained in the presentation is not to be taken as any recommendation made by the Company or any other person to enter into any agreement with regard to any investment.

We request you to take the above on record and the same be treated as compliance under the applicable Regulations of SEBI Listing Regulations.

Encl.: a/a.
Thanking You,
For Camlin Fine Sciences Limited

RAHUL SAWALE

Digitally signed by RAHUL SAWALE
Date: 2026.08.11 16:38:42 +05'30'

Rahul Sawale
Company Secretary
& VP - Legal

BLENDING
STRENGTH.
BUILDING
THE HIVE.

Camlin Fine Sciences Limited

Investor Presentation – August 2026

Safe Harbour

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Camlin Fine Sciences Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

Q1FY27
Financial Highlights

Q1FY27 Financial Highlights – Continuing Operations

Camlin Fine Sciences

Revenue (Rs. In Mn)



Operational EBITDA (Rs. In Mn)



EBITDA Margin %



PAT (Rs. In Mn)



On Consolidated Basis

*EBITDA is adjusted for FX loss

Highest Ever Quarterly Revenue

Financial Performance

- *Revenue at Rs 5,199 mn, up 27.5% YoY*
- *Gross margin at 41.2% (48.5% in Q4 FY26) on higher RM prices, limited pass-through, and liquidity issues; consequentially 159 bps negative impact on underlying EBITDA*
- *Operating expenses remain under control*
- *EBITDA for the quarter stood at Rs 176 mn; margin 3.4%*
- *Exceptional item of Rs 111 mn – being shortfall in settlement of insurance claim for fire at Brazil unit*

Operating Environment

- *Continued impact due to higher raw material prices*
- *Higher logistics cost, longer delivery times, elongated working capital cycle*

Segmental Highlights

- *Straights: revenue Rs 927 mn, up 41% on YoY basis despite high competition*
- *Blends: revenue up 35% on YoY basis; Vinpai contributed Rs 247 mn for the quarter*
- *Aroma: revenue grew by 37% on YoY basis with steady realisations and volumes of Vanillin*

Outlook – FY27

- *Blends: Growth momentum to continue across all geographies. Vitafor & Vinpai to stabilise*
- *Aroma: Improving growth trajectory of Vanillin with steady realisations. Aim to breakeven in coming quarters*
- *Lingering conflict situation may hamper transit time, operating cycle, and inflationary environment in the near term*

On Consolidated Basis

*EBITDA is adjusted for FX loss

Segmental Highlights – Q1FY27

Specialty Ingredients

STRAIGHTS	BLENDS
₹927 Revenue	₹3,086 Revenue
₹4,013 Total Revenue	6.35% EBITDA

Key Highlights

- Attractive growth markets across geographies
- Extensive product range – Clean label products
- New technologies & Functional Ingredients

Aroma

₹774
Revenue

(4.37)%
EBITDA

Key Highlights

- Tariff issues eased
- Margins to improve with enhanced utilization
- Methyl Vanillin Campaign in mid August

Performance Chemicals & Others

₹1,749
Revenue

(2.54)%
EBITDA

Key Highlights

- High costs impacting the vertical
- Diphenol plant is under shutdown
- Includes Intersegment transaction

Key Focus

To Improve Margins	Working Capital Cycle	New products in functional ingredients

Operational Revenue Breakup

Specialty Ingredients (Rs. In Mn) (Straights)



Specialty Ingredients (Rs. In Mn) (Value added blends)



Total Specialty Ingredients (Rs. In Mn)



Performance Chemicals & Others (Rs. In Mn)



Aroma Ingredients (Rs. In Mn)



On Consolidated Basis

Performance Chemicals revenue includes intersegment revenue

Adjusted EBITDA

Consolidated Profit & Loss Statement

CFS Camlin Fine Sciences

From Continuing Operations

Particulars (Rs. In Mn)	Q1 FY27	Q1 FY26	Q4 FY26	FY26
Revenue from Operation	**5,198.8**	**4,077.2**	**4,248.1**	**17,233.1**
Raw material consumption	3,056.8	2,256.9	2,187.9	9,224.5
Employee Cost	734.3	567.4	659.3	2,439.0
Other expenses	1,314.9	1,050.0	1,189.1	4,500.8
EBITDA	**92.7**	**202.9**	**211.9**	**1,068.8**
EBITDA Margins (%)	**1.8%**	**5.0%**	**5.0%**	**6.2%**
Adjusted EBITDA*	**176.4**	**202.9**	**211.9**	**1,068.8**
Adjusted EBITDA Margins (%)	**3.4%**	**5.0%**	**5.0%**	**6.2%**
Other Income	13.4	66.3	239.1	287.9
Depreciation	191.6	161.3	208.1	709.2
Finance cost	140.1	148.6	229.8	729.4
Exceptional Item	111.1	-	79.5	254.6
Share of profit / (loss) of associate	14.0	8.9	13.8	16.6
PBT	**(322.6)**	**(31.8)**	**(52.6)**	**(319.9)**
Tax	(4.6)	(0.3)	(62.4)	(4.6)
PAT	**(318.0)**	**(31.5)**	**9.7**	**(315.3)**

From Discontinued Operations#

PBT from discontinued operation	(18.3)	(75.3)	854.7	552.4
Tax expense of discontinued operations	-	-	1.7	1.7
PAT including Discontinued Operations	**(18.3)**	**(75.3)**	**853.0**	**550.7**

*EBITDA is adjusted for FX loss

Pertains to CFS Europe and CFSWL discontinued operations

Company Overview

Company Overview

Camlin Fine Sciences

Among Global Leaders

In the Manufacturing of Antioxidants

Preferred Partner

For Customized Shelf-Life Solutions

High Quality & Wide Range

Vanillin Manufacturer

100+

Range of Diversified Products

50,000+ MTPA

Led by Integrated Global Production Capacity

Catering Diverse Industries

Food & Beverage	Animal Nutrition	Pet Food
Pharmaceuticals & Pharma Intermediates	Petrochemicals	Dyes & Pigments
Poultry & Livestock	Bio-Fuels	Aquaculture & Fishmeal
Flavours & Fragrances	Dietary Supplements	Personal Care & Home Care
Polymers	Agrochemicals	Incense Sticks

Global specialty ingredients company providing Shelf-life, Aroma and Performance solutions

80+ Countries

1,300+ Customers Worldwide

8 Global Manufacturing Facilities

7 Application Laboratories

2 R&D Centers

FY26 Revenue Mix*#
₹ 17,233 mn



Excludes CFS Europe and CFSWL discontinued operations

From Manufacturing to Global Partnerships



1 Manufacturing Backbone

India | Brazil | Mexico | France | Belgium

Scale. Reliability. Consistency.

Core production hubs anchor the network, ensuring uninterrupted supply and quality.

2 Innovation Close to Market

Americas | Europe | Asia

Co-create. Customize. Accelerate.

Application labs and R&D centres enable faster response and tailored solutions.

3 Market Reach

80+ Countries

Local relevance. Global strength.

Deep market understanding supports customer alignment across regional needs and regulations.

4 Customer Partnerships

1,300+ Customers Worldwide

Localized expertise. Agility. Trust.

Serving global leaders and emerging innovators through flexible, long-term relationships.

From continued operations   Map not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Product Highlights

Camlin Fine Sciences

	FY26 Sales%*#	Key Products	End User Industries	Key Brands
Specialty Ingredients – Straights	18%	› TBHQ › BHA › Ascorbyl palmitate (ASP)	› Pet Food › Livestock Nutrition › Food & Beverages › Fish Meal › Animal Feed Mills › Biodiesel › Aquaculture & Fishmeal › Rendering	NaSure (Extending Shelf Life Naturally); BIOSUS OMEGA 20; Xtendra (shelf life solutions); BIOSUS DHA; Vinpai
Specialty Ingredients – Value added Blends	58%	› 200+ custom formulations, encompassing both traditional and natural solutions (forward-integrated antioxidant blends)	› These formulations are specifically tailored to meet the diverse needs of the industry › Aim to increase focus on high-value blends and additives	
Performance Chemicals & Others	10%	› HQ derivatives products like Chloranil, MEHQ, HQEE, TBHQ, PDMB, CME, › CT derivative products like 4 TBC, Guethol, Veratrole, Guaiacol, 1, 2MDB	› Petrochemicals › Dyes & Pigments › Agrochemicals › Polymers › Pharmaceuticals › Acrylates › Electroplating › Printing Inks	Dinamic (Performance Chemicals)
Aroma Ingredients	14%	› Vanillin, Ethyl Vanillin and Vanillin ex-clove (adorr™)	› Food & Beverages › Pharmaceutical › Incense sticks › Animal Feed › Flavors & Fragrance › Agrochemicals › Personal Care	adorr (sensory sciences)

From continued operations

1. a. Speciality Ingredients - Straights

Key Products

TBHQ
Highly effective antioxidant for protection against oxidative degradation.

BHA
Widely used antioxidant to preserve quality and extend shelf life.

Ascorbyl Palmitate
Fat-soluble antioxidant that helps maintain color, flavor and nutritional value

Key Brands

NaSure – Extending Shelf Life Naturally

BIOSUS™ OMEGA 20 – 20% DHA from algal biomass

Xtendra – shelf life solutions

BIOSUS DHA – Clean DHA from algal source

Key End User Industries

- Livestock Nutrition
- Pet Food
- Food & Beverages
- Biodiesel
- Animal Feed Mills
- Aquaculture & Fishmeal
- Rendering

Revenue Trend (Rs Mn)



From continued operations

1. b. Speciality Ingredients – Value Added Blends

Camlin Fine Sciences

Key Products

- 200+ custom formulations, encompassing both traditional and natural solutions (forward-integrated antioxidant blends)
- Forward-integrated blends (TBHQ, BHA, BHT, ASP) effectively extend shelf life and prevent food/feed loss/wastage.

Key Brands

Xtendra shelf life solutions

Vinpai

BIOSUS DHA Clean DHA from algal source

VITAFOR

Key End User Industries

Bakery Products | Pet Food | Livestock Nutrition | Biodiesel | Animal Feed Mills | Oils & Fats | Rendering

Revenue Trend (Rs Mn)



From continued operations

Expanding Global Reach in Blends

Camlin Fine Sciences

Vitafor

Acquisition of Vitafor Invest NV

100% stake

TRANSACTION SNAPSHOT

- 100% stake acquired
- Cash consideration: €1 Mn
- Belgium-based platform

BUSINESS PROFILE

- Animal-feed ingredient manufacturer and trader
- Located near Port of Antwerp
- Established European network

STRATEGIC VALUE

- Strengthens European & African reach
- Expands Pet Food & Feed exposure
- Creates Portfolio of cross-selling opportunities

PRODUCT / APPLICATION FOCUS

- Animal feed ingredients
- Nutritional additives
- Specialty feed solutions

Vinpai

Strategic majority acquisition in Vinpai S.A.

Majority stake

TRANSACTION SNAPSHOT

- ~83.82% Stake acquired in Dec -2025
- Post open offer, company now holds 95.41%

BUSINESS PROFILE

- Ingredient-tech company
- Natural and functional systems
- Algae, plant, mineral & fibre-based solutions

STRATEGIC VALUE

- Deepens food-ingredient capabilities
- Adds functional blend portfolio
- Supports cross-technology innovation

PRODUCT / APPLICATION FOCUS

- Functional ingredients
- Emulsifier systems
- Processed-cheese solutions

Strategic Impact

Broader portfolio | New geographies | Cross-selling opportunities | Enhanced innovation capabilities

2. Aroma Chemicals

Key Products

Vanillin
Manufacture Methyl Vanillin under Vanesse™ serving multiple industries

Ethyl Vanillin
Manufacture Ethyl Vanillin under Evanil™ serving multiple industries

Vanillin Ex-Clove
Adorr™ vanillin range is manufactured inhouse ensuring consistent quality, reliable supply, and complete traceability.

Key End User Industries

Food & Beverages
Flavours & Fragrance
Pharmaceuticals
Incense Sticks
Animal Feed
Agrochemicals
Livestock Nutrition

Revenue Trend (Rs Mn)



Key Brands

adorr VANILLIN US NATURAL
adorr VANILLIN premium
adorr VANILLIN free flow
adorr VANILLIN SOLUTIONS™
adorr ETHYL VANILLIN premium
INTENSE GREEN DIMETHYL HYDROQUINONE (DMHQ)

From continued operations

3. Performance Chemicals & Others

Key Products

HQ Derivatives

- Chloranil
- MEHQ
- HQEE
- TBHQ
- PDMB
- CME

Catechol Derivatives

- 4 TBC
- Guethol
- Veratrole
- Guaiacol
- 1, 2MDB

Key End User Industries

Petrochemicals | Dyes & Pigments | Acrylates | Agrochemicals

Electroplating | Pharmaceuticals | Polymers | Printing Inks

Key Brands

Dinamic
Performance Chemicals

From continued operations

Strategic Focus Areas across Segments

1. Speciality Ingredients (Straights + Blends + Vitafor + Vinpai)

AMEA Region

- **Portfolio Expansion -** Expand Xtendra®, NaSure®, and Enzentia® across food, functional ingredients, and animal nutrition
- **Domestic Market Expansion** – Strengthen poultry and scale aquaculture
- **Export Growth** - Expand internationally, especially in the Middle East.
- **Growth & Market Positioning** - Outpace industry growth through innovation and wider reach

America Region

- **Speciality Solutions -** Scale Xtendra®, NaSure®, Ezential® and Vinpai across food markets
- **Animal Nutrition Growth** – Expand performance nutrition, gut health and Vitafor™ solutions
- **Biodiesel Expansion** - Grow Brazil market share through scale and innovation.
- **Market Development** - Deepen customer partnerships and enter aquaculture and water treatment.

Europe Region

- Expansion into high-potential markets
- Increased adoption of farm-level performance solutions
- Product Development with increased focus on ruminant nutrition
- Continued integration with global Animal Nutrition platform

2. Aroma Chemicals

- Deepened partnerships with key accounts
- Ongoing efforts to strengthen presence in core geographies
- Expansion with select high value customers across other regions
- Continued focus on quality, reliability and service excellence
- Optimizing supply chain and cost structures

3. Performance Chemicals & Others

- Accelerate towards Speciality applications
- Expand presence in high-performance segments to reduce dependence on commodity price cycles
- Building on Diphenol platform and leveraging R&D capabilities

From continued operations

ESG

Environmental

- Transitioned from periodic monitoring to real-time environmental visibility through online installations, infrastructure upgrades
- Undertook comprehensive thermal insulation program to minimize heat loss and optimize energy

Social

- Completely renovated the Occupational Health Centre (OHC) to strengthen employee healthcare infrastructure.
- Enhanced medical surveillance and wellness support for employees.
- Successfully completed SEDEX audits, validating responsible workplace practices
- Continued investment in workplace health, safety and inclusivity, particularly across manufacturing plants.

Governance

- Diverse and experienced Board composition spanning technical and commercial expertise.
- Regular, solutions-focused Board sessions to refine corporate policies and strategic priorities.
- Strengthened risk-management practices aligned with the Company's ESG objectives.
- Progressed the FY2025–26 Global Reporting Initiative (GRI) assignment to strengthen sustainability reporting.

Board of Directors

	**Ashish Dandekar** ***Chairman & Managing Director***	› Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information systems, research & development, product development, and marketing › Holds a BA in Economics and Management studies from Temple University, USA		**Amol Shah** ***Independent Director***	› Managing Director of the MJ Group with over three decades of experience covering human healthcare, F&F compounds, plant protection, and water treatment chemicals › Holds an MBA from the University of Southern California and a Bachelor's in Engineering from the University of Kent
	**Nirmal Momaya** ***Managing Director***	› Qualified Chartered Accountant with over three decades of experience in finance, taxation, audit, and management consultancy › He has been instrumental in providing strategic guidance & direction to the company on all significant business matters		**Mahabaleshwar Palekar** ***Independent Director***	› Over three decades of experience with corporates in India and MNCs › Chemical engineer with a degree from the Institute of Chemical Technology (ICT) in Mumbai, India
	**Arjun Dukane** ***Executive Director-Technical***	› Chemical Engineer with over three decades of experience in the chemical industry › Has been associated with CFS for more than 15 years		**Joseph Conrad D'souza** ***Independent Director***	› Erstwhile Member of Executive Management and Ex-Chief Investor Relations Officer of HDFC Ltd › Holds an M.com from Mumbai University and an MBA from South Gujarat University
	**Harsha Raghavan** ***Non-Executive Non-Independent Director***	› Managing Partner of Convergent Finance LLP and ex-founding MD & CEO of Fairbridge Capital (a Fairfax Company) › Holds an MBA & MSc in industrial engineering from Stanford University and a B.A from University of California, Berkeley		**Pradip Kanakia** ***Independent Director***	› Qualified Chartered Accountant (both England, Wales and India) with over three decades of experience › Held leadership position in PWC & KPMG, leveraging his expertise in strategy, transformation, performance management, accounting, auditing, reporting, controls, compliance & governance
	**Anagha Dandekar** ***Non-Executive Non-Independent Director***	› President & co-founder of Hardware Renaissance, a manufacturer of handcrafted door hardware and accessories › Holds an MBA in Finance from the University of South Carolina, USA		**Abeezar Faizullabhoy** ***Independent Director***	› Senior Partner at Argus Partners (Solicitors & Advocates) – Mumbai and ex-partner of J Sagar Associates › Holds Bachelor of Law from University of Mumbai and a Qualified Solicitor from Bombay incorporated law society › Was previously on Board of CFS for 13 years till 2019, His immense experience in the Corporate commercial, litigation, M&A
	**Jens Van Nieuwenborgh** ***Non-Executive Non-Independent Director***	› Board member of several companies across India and Europe, with extensive experience in business administration, finance, and operations › Holds an MBA from Harvard University and a Master's in Science from Ghent University, Belgium.		**Radhika Dudhat** ***Independent Director***	› Over three decades of experience with corporates in India and MNCs › Partner with Shardul Amarchand Mangaldas & Co. and has worked on a wide range of transactional, regulatory and legal risk management advisory › Holds degrees in Life Sciences and Law from the University of Bombay, with postgraduate studies at Cambridge and Harvard.

Senior Management Team

Ashish Dandekar **Chairman & Managing Director**	› Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information systems, research & development, product development, and marketing › Holds a BA in Economics and Management studies from Temple University, USA
Nirmal Momaya ***Managing Director***	› Qualified Chartered Accountant with over three decades of experience in finance, taxation, audit, and management consultancy › He has been instrumental in providing strategic guidance & direction to the company on all significant business matters
Arjun Dukane ***Executive Director- Technical***	› Chemical Engineer with over three decades of experience in the chemical industry › Has been associated with CFS for more than 15 years
Santosh Parab ***Chief Financial Officer***	› Over two decades of experience working auditing profession › Previously worked at renowned Indian accounting firm › Qualified Chartered Accountant with a Bachelor's degree in commerce › Associated with CFS for more than 10 years
Nilesh Jadhav ***Chief Operating Officer***	› Chemical Engineer with around three decades of experience in the chemical industry including heading multilocational manufacturing sites › Previously worked at Balaji Amines, Deepak Fertilizers & Petrochemicals, Essar Refinery & Schenectady › Executive Management from IIM Bangalore and Piping Engineering from IIT Powai
Eric Santos ***Vice President – Aroma Ingredients***	› Over two decades of industry experience, previously worked as a commercial director at Solvay S.A. › Holds a Bachelor's degree in chemistry
Jose Arturo Paulin ***Head - Mexico operations***	› Over two decades of experience in the feed market (premix, feed additives, pet food, and rendering) › Previously worked at Trouw Nutrition and Kemin Inc in Mexico › Qualifed agriculture engineer
Jennifer Igou ***Head - USA operations***	› Over two decades of experience in food and pet-food space particularly in anti-oxidants & Hydrocolloids › Previously worked at Kemin Inc. USA & FMC › Holds a Bachelor's degree in Chemistry and Biology with an emphasis in Biomedicine

Historical Financial Highlights

Historical Financial Highlights

Revenue (Rs. In Mn)



EBITDA (Rs. In Mn)



PAT (Rs. In Mn)



Net Debt to Equity (x)



Net Debt to EBITDA (x)



On Consolidated Basis

Operational Revenue Break-up

Specialty Ingredients (Rs. In Mn) (Straights)



Specialty Ingredients (Rs. In Mn) (Value added blends)



Total Specialty Ingredients (Rs. In Mn)



Performance Chemicals & Others (Rs. In Mn)#



Aroma Ingredients (Rs. In Mn)



Total Revenue Breakup (%)*



On Consolidated Basis

*Excluding Other Products

FY24, FY25 & FY26 figures excludes Diphenol CFS Europe and entire CFSWL discontinued operations

#Performance Chemicals exclude intersegment revenue

Thank You !

Camlin Fine Sciences Ltd.
CIN – L74100MH1993PLCO75361
Santosh Parab- CFO
Email – santosh.parab@camlinfs.com
www.camlinfs.com

SGA Strategic Growth Advisors

Strategic Growth Advisors Pvt. Ltd.
CIN - U74140MH2010PTC204285
Shrikant Sangani / Shaily Patwa
Email – shrikant.sangani@sgapl.net / shaily.p@sgapl.net
Mobile No – 9619595686 / 9819494608
www.sgapl.net